3.4 Summary of Major Deals For perspective, Table 1 highlights key obesity/GLP-1 transactions and their deal values: Table 1: Selected major acquisitions and licensing deals in the obesity/GLP-1 sector (20232025)
found that treatment with GLP-1RA leads to a 17% reduction in a broad composite kidney endpoint (development of new-onset macroalbuminuria, doubling of serum creatinine or 40% greater decline in estimated glomerular filtration rate (eGFR), progression to end-stage kidney disease, or kidney-related death), mainly as a result of a reduction in new-onset macroalbuminuria (15)
PARP inhibitors: Synthetic lethality in the clinic
Acetyl-L- carnitine modulates glucose metabolism and stimulates glycogen synthesis in rat brain Brain Res 1998
[We need] things that these consumers really want to eat. What that small package should look like, however, is still somewhat in question
cAMP also activates the PKA/MAPK pathway and increases synaptic plasticity